August 20, 2007 - EDAP TMS S.A., a provider of High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, is currently conducting clinical investigations in France under an approved clinical trial combining the company's Ablatherm-HIFU device with chemotherapy, using docetaxel.
The study is a primary treatment therapy program for men suffering from clinically localized but aggressive high risk prostate cancer typically classified as stage T2c. The study began in late 2006 and will enroll a total of 30 men, of which more than 10 have already been treated.